Team

People behind the programme

Scientific leadership for the CHR-P programme, company leadership at the pharmaceutical sponsor, and published advisers. Roles here are company and programme roles — they do not imply DAO board or treasury seats.

Last reviewed: 24 September 2026

Scientific leadership

Programme scientific leads for CHR-P and related psychiatric development. Individual scientific and company roles — not institutional endorsements of this website or any financing vehicle.

CHR-P programme lead

Professor Scott Woods

Individual scientific / programme leadership Individual capacity

Clinical high-risk-for-psychosis expertise supporting early identification, assessment, and intervention research.

More about this role

Yale Professor of Psychiatry and a recognised leader in CHR-P assessment instruments, including PSYCHS, SIPS, and Mini-SIPS. As CHR-P programme lead in an individual capacity, he guides scientific framing of assessment, enrichment, and intervention design for this workstream. NWPharmaTech remains pharmaceutical sponsor (CMC, safety, regulatory); investigators, ethics committees, and regulators remain independent.

Yale disclaimer: Professor Woods’s role is individual scientific and programme leadership. Yale University does not sponsor or endorse this website, the DAO, or any financing vehicle.

Dr Grace Blest-Hopley

Partner & Chief Scientific Officer

Company scientific leadership for NWPharmaTech’s research and development agenda, including the investigational CHR-P candidate.

More about this role

As Chief Scientific Officer, accountable for the company’s scientific agenda across research and development. For the CHR-P workstream this includes formulation characterisation and the scientific rationale for dose-response, symptom, safety and tolerability evaluation of investigational NWPT-SM32300. Effectiveness in this population has not been established.

Dr John Kane, MD

Lead — Schizophrenia Programme

Senior psychiatric leadership for the company’s schizophrenia development strategy and clinical programme.

More about this role

Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; former long-standing Chair of Psychiatry at Zucker Hillside Hospital. Affiliation listed for identification only — not an institutional endorsement of this website or any financing vehicle.

His published company role is leadership of the schizophrenia programme. First-episode and schizophrenia treatment research informs psychiatric development generally; it does not by itself establish CHR-P prevention claims for NWPT-SM32300.

Company leadership

NWPharmaTech remains the pharmaceutical sponsor for clinical development, safety, manufacturing quality (CMC), and regulatory strategy.

Filipp Korentsvit

Co-Founder & Chief Executive Officer

Corporate leadership for NWPharmaTech as pharmaceutical sponsor of the investigational CHR-P programme.

More about this role

Co-founder and CEO of NWPharmaTech. Company accountability for strategy and sponsorship of the investigational CHR-P programme. NWPharmaTech remains pharmaceutical sponsor (CMC, safety, regulatory); investigators, ethics committees, and regulators remain independent. Roles listed here are company roles — not DAO board or treasury seats.

Daud Gutseriev

Co-Founder & Chief Operating Officer

Corporate operations leadership for NWPharmaTech as pharmaceutical sponsor.

More about this role

Co-founder and COO of NWPharmaTech. Operational leadership at the pharmaceutical sponsor supporting delivery of company programmes, including the investigational CHR-P workstream. Listing here does not create DAO governance or treasury authority.

Advisers

Published company advisory and non-executive roles. Listing here does not create DAO governance or treasury authority.

Prof. Richard Barker, OBE

Partner & Senior Advisor

Senior company adviser on strategy and life-sciences development.

More about this role

Published partner and senior adviser role at NWPharmaTech, focused on strategy and life-sciences development. Advisory listing does not create DAO governance or treasury authority.

Prof. Trevor Jones

Partner & Senior Regulatory and Clinical Advisor

Senior regulatory and clinical adviser to the pharmaceutical sponsor.

More about this role

Published partner role focused on regulatory and clinical advice for NWPharmaTech as pharmaceutical sponsor. Advisory listing does not create DAO governance or treasury authority.

Gillian Cannon

Non-Executive Director · Commercial Committee

Former company president with senior commercial leadership experience at Merck & Co., Otsuka, UCB and Roivant Sciences.

More about this role

Non-executive commercial perspective for NWPharmaTech via the Commercial Committee. Listing here does not create DAO governance or treasury authority.

For press, research, or collaboration enquiries, use Contact.